Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide

Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide

Metabolic dysfunction-associated steatohepatitis (MASH) has cardiometabolic risk factors, such as obesity and type 2 diabetes, and has been reported to have a potentially higher risk of mortality than conventional steatotic liver diseases. Liver fibrosis develops and can progress to cirrhosis and he...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuki Oe, Takashi Omori, Eriko Aimono, Shin Furukawa, Hirohiko Kitakawa, Masatoshi Tateno, Kiyoshi Sakai, Kyu Yong Cho
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Endocrinology
Subjects:
glucose-dependent insulinotropic polypeptide
glucagon-like peptide 1 receptor
type 2 diabetes
metabolic dysfunction-associated steatohepatitis
obesity
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1501984/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items